Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00087724 · ClinicalTrials.gov registry record · Phase 2
A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2 study, sponsored by Astellas Pharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 510
- Enrollment target
NCT00087724: Clinical Trial Phase 2 study, sponsored by Astellas Pharma.
NCT00087724 is a Phase 2 study that was terminated before completion, run by Astellas Pharma. The registered enrollment target is 510 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (283% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00087724, a Phase 2 study, was terminated before completion, sponsored by Astellas Pharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 510 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of five fixed dosage levels of FK962 or placebo for 24 weeks in subjects with mild to moderate Alzheimer's disease. Patient visits are every six weeks with limited efficacy measurements at week 6 and 18.
Interventions
- DRUG FK962
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 510 participants |
| Start Date | 2004-07 |
| Est. Completion | 2006-09 |
| Phase | Phase 2 |
Why NCT00087724 stopped before completion
NCT00087724 is an interventional study that assigns participants to a tested intervention. The registered 510 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (283% higher).
The record links to 0 conditions, and to 1 intervention - of which FK962 is the first listed.
NCT00087724 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00087724 about?
NCT00087724 is a clinical study titled "A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease". The purpose of this study is to evaluate the safety and efficacy of five fixed dosage levels of FK962 or placebo for 24 weeks in subjects with mild to moderate Alzheimer's disease. Patient visits are every six weeks with limited efficacy measurements at week 6 and 18.
What is the current status of trial NCT00087724?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 510 participants. The study started on 2004-07. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00087724?
The interventions under investigation include: FK962 (DRUG).
Who is sponsoring clinical trial NCT00087724?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00087724's enrollment target sits among peer trials
510 68th of 2000 higher than 1,932 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03922542 · 510 participants · Phase 2
Comparison of Standard vs. Accelerated Corneal Crosslinking
- NCT04634552 · 510 participants · Phase 2
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- NCT05164744 · 510 participants
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
- NCT05451004 · 510 participants · Phase 3
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia